Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Infectious Disorders - Drug Targets (Formerly Current Drug Targets - Infectious Disorders)
  4. Fast Track Articles
  5. Fast Track Article
image of Design of RNA Polymerase Inhibitors as Therapeutics for Tuberculous Meningitis

Abstract

Background

Tuberculosis is an infectious disease caused by . The current treatment protocols for pulmonary tuberculosis are quite effective, even though the treatment requires 3-6 months. The current treatment protocols for extrapulmonary tuberculosis are based on the same drugs that are used for pulmonary tuberculosis. However, the success rates are much lower for certain types of extrapulmonary tuberculosis, such as tuberculous meningitis. Tuberculous meningitis is one of the very few diseases attributable to bacteria that have a very high short-term mortality rate among diagnosed patients, even after treatment with antibiotics that are effective for pulmonary tuberculosis. For example, rifampicin is highly effective for the treatment of pulmonary tuberculosis, but its effectiveness for the treatment of tuberculous meningitis is much lower. The reason for the lower effectiveness of rifampicin against tuberculous meningitis is that it has low Blood-Brain Barrier (BBB) permeability, which results in lower concentrations of the drug at the required sites in the central nervous system.

Methods

In this work, ligands having increased BBB permeability and pharmacokinetic and pharmacodynamic properties, either similar to or better than that of rifampicin, have been designed. The BBB permeability of the designed molecules was assessed by using pkCSM, a machine-learning model. Pharmacokinetic properties, drug-likeness, and synthesizability were assessed by using SWISS-MODEL. The binding affinity of the designed drugs was assessed by using AutoDock Vina. A customized scoring function, StWN score, was used for a quantitative weighted assessment of all the properties of interest to rank the designed molecules.

Results

In this study, drug-like ligands have been designed that have been predicted to have high BBB permeability as well as high affinity for RNA polymerase β of .

Conclusion

The best ligands generated by the tools employed were selected as potential drugs to address the current need for better options for the treatment of tuberculous meningitis.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/iddt/10.2174/0118715265341228240827062721
2024-09-02
2024-11-22

  • From This Site

    /content/journals/iddt/10.2174/0118715265341228240827062721
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. WHO Consolidated Guidelines on Tuberculosis Module 4, Treat-ment: Drug-Resistant Tuberculosis Treatment. Geneva: World Health Organization 2020
    [Google Scholar]
  2. Dheda K. Perumal T. Moultrie H. The intersecting pandemics of tuberculosis and COVID-19: Population-level and patient-level impact, clinical presentation, and corrective interventions. Lancet Respir. Med. 2022 10 6 603 622 10.1016/S2213‑2600(22)00092‑3 35338841
    [Google Scholar]
  3. Alipanah N. Jarlsberg L. Miller C. Adherence interventions and outcomes of tuberculosis treatment: A systematic review and meta-analysis of trials and observational studies. PLoS Med. 2018 15 7 e1002595 10.1371/journal.pmed.1002595 29969463
    [Google Scholar]
  4. Munro S.A. Lewin S.A. Smith H.J. Engel M.E. Fretheim A. Volmink J. Patient adherence to tuberculosis treatment: A systematic review of qualitative research. PLoS Med. 2007 4 7 e238 10.1371/journal.pmed.0040238 17676945
    [Google Scholar]
  5. Zaman K. Tuberculosis: A global health problem. J. Health Popul. Nutr. 2010 28 2 111 113 10.3329/jhpn.v28i2.4879 20411672
    [Google Scholar]
  6. Goldstein B.P. Resistance to rifampicin: A review. J. Antibiot. 2014 67 9 625 630 10.1038/ja.2014.107 25118103
    [Google Scholar]
  7. Somasundaram S. Ram A. Sankaranarayanan L. Isoniazid and rifampicin as therapeutic regimen in the current era: A review. J. Tuberc. Res. 2014 2 1 40 51 10.4236/jtr.2014.21005
    [Google Scholar]
  8. A Darst S. Bacterial RNA polymerase. Curr. Opin. Struct. Biol. 2001 11 2 155 162 10.1016/S0959‑440X(00)00185‑8 11297923
    [Google Scholar]
  9. Lee J. Borukhov S. Bacterial RNA polymerase-DNA interaction—the driving force of gene expression and the target for drug action. Front. Mol. Biosci. 2016 3 73 10.3389/fmolb.2016.00073 27882317
    [Google Scholar]
  10. Hubin E.A. Lilic M. Darst S.A. Campbell E.A. Structural insights into the mycobacteria transcription initiation complex from analysis of X-ray crystal structures. Nat. Commun. 2017 8 1 16072 10.1038/ncomms16072 28703128
    [Google Scholar]
  11. Rodrigue S. Provvedi R. Jacques P.É. Gaudreau L. Manganelli R. The σ factors of Mycobacterium tuberculosis. FEMS Microbiol. Rev. 2006 30 6 926 941 10.1111/j.1574‑6976.2006.00040.x 17064287
    [Google Scholar]
  12. Vassylyev D.G. Sekine S. Laptenko O. Crystal structure of a bacterial RNA polymerase holoenzyme at 2.6 Å resolution. Nature 2002 417 6890 712 719 10.1038/nature752 12000971
    [Google Scholar]
  13. Almeida Da Silva P.E. Palomino J.C. Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: Classical and new drugs. J. Antimicrob. Chemother. 2011 66 7 1417 1430 10.1093/jac/dkr173 21558086
    [Google Scholar]
  14. Campbell E.A. Korzheva N. Mustaev A. Structural mechanism for rifampicin inhibition of bacterial rna polymerase. Cell 2001 104 6 901 912 10.1016/S0092‑8674(01)00286‑0 11290327
    [Google Scholar]
  15. Zenkin N. Kulbachinskiy A. Bass I. Nikiforov V. Different rifampin sensitivities of Escherichia coli and Mycobacterium tuberculosis RNA polymerases are not explained by the difference in the beta-subunit rifampin regions I and II. Antimicrob. Agents Chemother. 2005 49 4 1587 1590 10.1128/AAC.49.4.1587‑1590.2005 15793146
    [Google Scholar]
  16. Smith M. Journeys in Medicine and Research on Three Continents Over 50 Years. WORLD SCIENTIFIC 2017 10.1142/10435
    [Google Scholar]
  17. Wilmott R.W. Kendig’s Disorders of the Respiratory Tract in Children. 9th ed Philadelphia, PA Elsevier 2019
    [Google Scholar]
  18. Jamieson F.B. Guthrie J.L. Neemuchwala A. Lastovetska O. Melano R.G. Mehaffy C. Profiling of rpoB mutations and MICs for rifampin and rifabutin in Mycobacterium tuberculosis. J. Clin. Microbiol. 2014 52 6 2157 2162 10.1128/JCM.00691‑14 24740074
    [Google Scholar]
  19. Muthaiah M. Shivekar S.S. Cuppusamy Kapalamurthy V.R. Alagappan C. Sakkaravarthy A. Brammachary U. Prevalence of mutations in genes associated with rifampicin and isoniazid resistance in Mycobacterium tuberculosis clinical isolates. J. Clin. Tuberc. Other Mycobact. Dis. 2017 8 19 25 10.1016/j.jctube.2017.06.001 31723707
    [Google Scholar]
  20. Rukasha I. Said H.M. Omar S.V. Correlation of rpoB mutations with minimal inhibitory concentration of rifampin and rifabutin in Mycobacterium tuberculosis in an HIV/AIDS endemic setting, South Africa. Front. Microbiol. 2016 7 1947 10.3389/fmicb.2016.01947 27994580
    [Google Scholar]
  21. Cresswell F.V. Te Brake L. Atherton R. Intensified antibiotic treatment of tuberculosis meningitis. Expert Rev. Clin. Pharmacol. 2019 12 3 267 288 10.1080/17512433.2019.1552831 30474434
    [Google Scholar]
  22. Garg R.K. Rizvi I. Malhotra H.S. Uniyal R. Kumar N. Management of complex tuberculosis cases: A focus on drug-resistant tuberculous meningitis. Expert Rev. Anti Infect. Ther. 2018 16 11 813 831 10.1080/14787210.2018.1540930 30359140
    [Google Scholar]
  23. Donovan J. Thwaites G.E. Huynh J. Tuberculous meningitis: Where to from here? Curr. Opin. Infect. Dis. 2020 33 3 259 266 10.1097/QCO.0000000000000648 32324614
    [Google Scholar]
  24. Jumper J. Evans R. Pritzel A. Highly accurate protein structure prediction with AlphaFold. Nature 2021 596 7873 583 589 10.1038/s41586‑021‑03819‑2 34265844
    [Google Scholar]
  25. Daina A. Michielin O. Zoete V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. Rep. 2017 7 1 42717 10.1038/srep42717 28256516
    [Google Scholar]
  26. Morris G.M. Huey R. Lindstrom W. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J. Comput. Chem. 2009 30 16 2785 2791 10.1002/jcc.21256 19399780
    [Google Scholar]
  27. Trott O. Olson A.J. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 2010 31 2 455 461 10.1002/jcc.21334 19499576
    [Google Scholar]
  28. Sunseri J. Koes D.R. Pharmit: Interactive exploration of chemical space. Nucleic Acids Res. 2016 44 W1 W442-8 10.1093/nar/gkw287 27095195
    [Google Scholar]
  29. Green H. Koes D.R. Durrant J.D. DeepFrag: A deep convolutional neural network for fragment-based lead optimization. Chem. Sci. 2021 12 23 8036 8047 10.1039/D1SC00163A 34194693
    [Google Scholar]
  30. Durrant J.D. Amaro R.E. McCammon J.A. AutoGrow: A novel algorithm for protein inhibitor design. Chem. Biol. Drug Des. 2009 73 2 168 178 10.1111/j.1747‑0285.2008.00761.x 19207419
    [Google Scholar]
  31. Ertl P. Schuffenhauer A. Estimation of synthetic accessibility score of drug-like molecules based on molecular complexity and fragment contributions. J. Cheminform. 2009 1 1 8 10.1186/1758‑2946‑1‑8 20298526
    [Google Scholar]
  32. Mendelsohn L.D. Chemdraw 8 ultra, windows and macintosh versions. J. Chem. Inf. Comput. Sci. 2004 44 6 2225 2226 10.1021/ci040123t
    [Google Scholar]
  33. The PyMOL Molecular Graphics System
  34. Owoloye A.J. Ligali F.C. Enejoh O.A. Molecular docking, simulation and binding free energy analysis of small molecules as PfHT1 inhibitors. PLoS One 2022 17 8 e0268269 10.1371/journal.pone.0268269 36026508
    [Google Scholar]
  35. Pires D.E.V. Blundell T.L. Ascher D.B. pkCSM: Predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures. J. Med. Chem. 2015 58 9 4066 4072 10.1021/acs.jmedchem.5b00104 25860834
    [Google Scholar]
  36. Wilkinson R.J. Rohlwink U. Misra U.K. Tuberculous meningitis. Nat. Rev. Neurol. 2017 13 10 581 598 10.1038/nrneurol.2017.120 28884751
    [Google Scholar]
/content/journals/iddt/10.2174/0118715265341228240827062721
Loading
Design of RNA Polymerase Inhibitors as Therapeutics for Tuberculous Meningitis
Bentham Science Publishers ; https://doi.org/10.2174/0118715265341228240827062721
/content/journals/iddt/10.2174/0118715265341228240827062721
/content/journals/iddt/10.2174/0118715265341228240827062721
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: tuberculous meningitis ; Tuberculosis ; Mycobacterium tuberculosis ; extrapulmonary tuberculosis ; blood-brain barrier permeability ; rifampicin

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test